MA53743A - Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 - Google Patents
Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3Info
- Publication number
- MA53743A MA53743A MA053743A MA53743A MA53743A MA 53743 A MA53743 A MA 53743A MA 053743 A MA053743 A MA 053743A MA 53743 A MA53743 A MA 53743A MA 53743 A MA53743 A MA 53743A
- Authority
- MA
- Morocco
- Prior art keywords
- aging
- compositions
- methods
- disorders related
- treating disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53743A true MA53743A (fr) | 2022-01-05 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053743A MA53743A (fr) | 2018-09-26 | 2019-09-25 | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (fr) |
| JP (1) | JP2022502441A (fr) |
| KR (1) | KR20210065950A (fr) |
| CN (1) | CN112789044A (fr) |
| AU (1) | AU2019346456A1 (fr) |
| BR (1) | BR112021004938A2 (fr) |
| CA (1) | CA3111433A1 (fr) |
| CL (1) | CL2021000724A1 (fr) |
| CO (1) | CO2021003713A2 (fr) |
| EA (1) | EA202190463A1 (fr) |
| IL (1) | IL281578A (fr) |
| MA (1) | MA53743A (fr) |
| MX (1) | MX2021002967A (fr) |
| SG (1) | SG11202102105VA (fr) |
| TW (1) | TW202027752A (fr) |
| WO (1) | WO2020069008A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (fr) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| KR102658724B1 (ko) * | 2017-04-05 | 2024-04-18 | 알카헤스트 인코포레이티드 | Ccr3-저해제를 사용하여 망막-관련 질병을 치료하는 방법 및 조성물 |
| CN110636844A (zh) * | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
-
2019
- 2019-09-25 JP JP2021517342A patent/JP2022502441A/ja active Pending
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 CA CA3111433A patent/CA3111433A1/fr active Pending
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/fr active Pending
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/fr active Application Filing
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210065950A (ko) | 2021-06-04 |
| EA202190463A1 (ru) | 2021-06-29 |
| IL281578A (en) | 2021-05-31 |
| TW202027752A (zh) | 2020-08-01 |
| EP3856195A4 (fr) | 2022-06-22 |
| BR112021004938A2 (pt) | 2021-06-01 |
| MX2021002967A (es) | 2021-08-11 |
| CN112789044A (zh) | 2021-05-11 |
| SG11202102105VA (en) | 2021-04-29 |
| JP2022502441A (ja) | 2022-01-11 |
| CO2021003713A2 (es) | 2021-04-08 |
| EP3856195A1 (fr) | 2021-08-04 |
| CL2021000724A1 (es) | 2021-10-15 |
| WO2020069008A1 (fr) | 2020-04-02 |
| AU2019346456A1 (en) | 2021-04-15 |
| CA3111433A1 (fr) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
| MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA51316A (fr) | Compositions et méthodes permettant de traiter les troubles du snc | |
| JOP20220243A1 (ar) | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة | |
| MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA49069A (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
| MA51315A (fr) | Compositions et méthodes permettant de traiter des troubles du snc | |
| EA201101009A1 (ru) | АНТАГОНИСТЫ C5aR | |
| MA53445A (fr) | Procédés et compositions pour la modification de plantes | |
| MA44886A (fr) | Compositions et méthode pour traiter des troubles acide-base | |
| MA45341A (fr) | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive | |
| MA53234A (fr) | Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques | |
| MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| MA54874A (fr) | Compositions et procédés de traitement des troubles neurocognitifs | |
| TN2016000040A1 (fr) | Inhibiteurs de porc2 et procedes pour leur utilisation | |
| IL276158A (en) | Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors | |
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| IL289173A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| SG11202104053TA (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| SG11202112515RA (en) | Methods and compositions for treating liver disorders |